[1]
|
Ohno-Shosaku, T., Tanimura, A., Hashimotodani, Y., et al. (2012) Endocannabinoids and Retrograde Modulation of Synaptic Transmission. Neuroscientist, 18, 119-132. https://doi.org/10.1177/1073858410397377
|
[2]
|
Xu, J. and Chen, C. (2015) Endocannabinoids in Synaptic Plasticity and Neuroprotection. Neuroscientist, 21, 152-168.
https://doi.org/10.1177/1073858414524632
|
[3]
|
朱时钰, 杨红卫. 大麻素2型受体在帕金森病中的神经保护作用研究进展[J]. 生命的化学, 2018, 38(4): 529-533.
|
[4]
|
Scotter, E.L., Abood, M.E. and Glass, M. (2010) The Endocannabinoid System as a Target for the Treatment of Neurodegenerative Disease. British Journal of Pharmacol-ogy, 160, 480-498.
https://doi.org/10.1111/j.1476-5381.2010.00735.x
|
[5]
|
Zhang, L., Wang, M., Bisogno, T., Di Marzo, V. and Alger, B.E. (2011) Endocannabinoids Generated by Ca2+or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase. PLoS ONE, 6, e16305.
https://doi.org/10.1371/journal.pone.0016305
|
[6]
|
Raskin, J., Cummings, J., Hardy, J., Schuh, K. and Dean, R.A. (2015) Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research, 12, 712-722. https://doi.org/10.2174/1567205012666150701103107
|
[7]
|
Chen, R., Zhang, J., Wu, Y., et al. (2012) Monoacylglycer-ol Lipase Is a Therapeutic Target for Alzheimer’s Disease. Cell Reports, 2, 1329-1339. https://doi.org/10.1016/j.celrep.2012.09.030
|
[8]
|
Schmöle, A.C., Lundt, R., Toporowski, G., Hansen, J.N., et al. (2018) Cannabinoid Receptor 2-Deficiency AmelioratesDisease Symptoms in a Mouse Model with Alzheimer’s Dis-ease-Like Pathology. Journal of Alzheimer’s Disease, 64, 379-392. https://doi.org/10.3233/JAD-180230
|
[9]
|
Gauthier, A., Vassiliou, G., Benoist, F., et al. (2003) Adipocyte Low Density Lipoprotein Receptor-Related Protein Gene Expression and Function Is Regulated by Peroxisome Prolifera-tor-Activated Receptor γ. Journal of Biological Chemistry, 278, 11945-11953. https://doi.org/10.1074/jbc.M212989200
|
[10]
|
Tolón, R.M., Núñez, E., Pazos, M.R., et al. (2009) The Activation of Cannabinoid CB2 Receptors Stimulates in Situ and in Vitro Beta-Amyloid Removal by Human Macrophages. Brain Research, 1283, 148-154.
https://doi.org/10.1016/j.brainres.2009.05.098
|
[11]
|
Chen, X., Zhang, J. and Chen, C. (2011) Endocanna-binoid 2-Arachidonoylglycerol Protects Neurons against β-Amyloid Insults. Neuroscience, 178, 159-168. https://doi.org/10.1016/j.neuroscience.2011.01.024
|
[12]
|
Wu, J., Bie, B., Yang, H., et al. (2013) Activation of the CB2 Receptor System Reverses Amyloid-Induced Memory Deficiency. Neurobiology of Aging, 34, 791-804. https://doi.org/10.1016/j.neurobiolaging.2012.06.011
|
[13]
|
Wolff, M.C. and Leander, J.D. (2003) SR141716A, a Cannabinoid CB1 Receptor Antagonist, Improves Memory in a Delayed Radial Maze Task. European Journal of Pharmacology, 477, 213-217.
https://doi.org/10.1016/j.ejphar.2003.08.025
|
[14]
|
Martin-Moreno, A.M., Brera, B., Spuch, C., et al. (2012) Prolonged Oral Cannabinoid Administration Prevents Neuroinflammation, Lowers Beta-Amyloid Levels and Im-proves Cognitive Performance in Tg APP 2576 Mice. Neuroinflammation, 9, 8. https://doi.org/10.1186/1742-2094-9-8
|
[15]
|
Ozaita, A., Puighermanal, E. and Maldonado, R. (2007) Regula-tion of PI3K/Akt/GSK-3 Pathway by Cannabinoids in the Brain. Journal of Neurochemistry, 102, 1105-1114. https://doi.org/10.1111/j.1471-4159.2007.04642.x
|
[16]
|
Giuffrida, A., Parsons, L.H., Kerr, T.M., et al. (1999) Dopa-mine Activation of Endogenous Cannabinoid Signaling in Dorsal Striatum. Nature Neuroscience, 2, 358-363. https://doi.org/10.1038/7268
|
[17]
|
Marinelli, S, Di Marzo, V., Florenzano, F., Fezza, F., et al. (2007) N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating Both Canna-binoid and Vanilloid Receptors. Neuropsychopharmacology, 32, 298-308. https://doi.org/10.1038/sj.npp.1301118
|
[18]
|
邹梓良, 查运红, 杨红卫. 内源性大麻素系统与帕金森病关系的研究进展[J]. 广东医学, 2015, 36(9): 1449-1451.
|
[19]
|
Kreitzer, A.C. and Malenka, R.C. (2005) Dopamine Modulation of State Dependent Endocannabinoid Release and Long-Term Depression in the Striatum. Neuroscience, 25, 10537-10545.
https://doi.org/10.1523/JNEUROSCI.2959-05.2005
|
[20]
|
Venderova, K., Ruzicka, E., Vorisek, V. and Visnovsky, P. (2004) Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms. Movement Disorders, 19, 1102-1106. https://doi.org/10.1002/mds.20111
|
[21]
|
Wong, P., Pardo, C., Borchelt, D., et al. (1995) An Adverse Property of a Familial ALS-Linked SOD1 Mutation Causes Motor Neuron Disease Charac-terized by Vacuolar Degeneration of Mitochondria. Neuron, 14, 1105-1116.
https://doi.org/10.1016/0896-6273(95)90259-7
|
[22]
|
Bruijn, L., Becher, M., Lee, M., et al. (1997) ALS-Linked SOD1 Mutant G85R Mediates Damage to Astro-Cytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions. Neuron, 18, 327-338.
https://doi.org/10.1016/S0896-6273(00)80272-X
|
[23]
|
Bilsland, L.G., Dick, J.R., Pryce, G., et al. (2006) In-creasing Cannabinoid Levels by Pharmacological and Genetic Manipulation Delay Disease Progression in SOD1 Mice. FASEB Journal, 29, 29. https://doi.org/10.1096/fj.05-4743fje
|
[24]
|
Kim, K., Moore, D.H., Makriyannis, A., et al. (2006) AM1241, a Cannabinoid CB2 Receptor Selective Compound, Delays Disease Pro-Gression in a Mouse Model of Amyotrophic Lateral Sclerosis. European Journal of Pharmacology, 542, 100-105. https://doi.org/10.1016/j.ejphar.2006.05.025
|
[25]
|
Zhao, P., Ignacio, S., Beattie, E.C., et al. (2008) Altered Pre-symptom-Atic AMPA and Cannabinoid Receptor Trafficking in Motor Neurons of ALS Model Mice: Implications for Excitotoxicity. European Journal of Neuroscience, 27, 572-579. https://doi.org/10.1111/j.1460-9568.2008.06041.x
|
[26]
|
Rossi, S., De Chiara, V., Musella, A., et al. (2010) Abnormal Sensitivity of Cannabinoid CB1 Receptors in the Striatum of Mice with Experimental Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis, 19, 1-8.
https://doi.org/10.3109/17482960902977954
|
[27]
|
Rothstein, J.D., Patel, S., Regan, M.R., et al. (2005) Be-ta-Lactam Antibiotics Offer Neuroprotection by Increasing Glutamate Transporter Expression. Nature, 433, 73-77. https://doi.org/10.1038/nature03180
|